Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review
Serious adverse events or adverse events · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Statins for asthma 2020 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Serious adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in serious adverse events (Panaccione 2010) compared with placebo (low certainty).
1 finding from 1 review
Adverse events (non‐serious and serious) · people with diabetes and foot ulcers
Any growth factor showed no clear difference in adverse events (non‐serious and serious) compared with placebo or no growth factor (low certainty).
1 finding from 1 review
Serious adverse events until data cut‐offb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in serious adverse events until data cut‐offb compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events during the study period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes serious adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serioushypertension · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Adverse events of any severity or seriousness · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events by total adverse events · patients with upper gastrointestinal bleeding and liver diseases.
Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).
1 finding from 1 review